AM
REGN icon

AGF Management’s Regeneron Pharmaceuticals REGN Stock Holding History

AGF Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Sell
415
-5
-1% -$3.83K ﹤0.01% 617
2025
Q4 		$324K Sell
420
-10
-2% -$6.79K ﹤0.01% 621
2025
Q3 		$242K Sell
430
-15
-3% -$8.48K ﹤0.01% 637
2025
Q2 		$234K Sell
445
-798
-64% -$445K ﹤0.01% 615
2025
Q1 		$788K Sell
1,243
-34
-3% -$23.4K ﹤0.01% 560
2024
Q4 		$910K Buy
1,277
+942
+281% +$791K ﹤0.01% 581
2024
Q3 		$352K Sell
335
-6
-2% -$6.68K ﹤0.01% 649
2024
Q2 		$358K Sell
341
-815
-71% -$790K ﹤0.01% 657
2024
Q1 		$1.11M Buy
1,156
+428
+59% +$407K 0.01% 561
2023
Q4 		$639K Buy
+728
New +$600K ﹤0.01% 606
2023
Q1 		– Sell
-437
Closed -$315K – 805
2022
Q4 		$315K Buy
+437
New +$322K ﹤0.01% 725

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AGF Management's REGN Position: Q1 2026 in Review

AGF Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q1 2026, selling an estimated $3.83K and leaving 415 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

AGF Management first reported a position in REGN in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.11M in Q1 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • AGF Management held 415 shares of Regeneron Pharmaceuticals worth $321K as of Q1 2026.
  • AGF Management sold 5 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.83K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of AGF Management's portfolio in Q1 2026, its #617 holding.
  • AGF Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • AGF Management's Regeneron Pharmaceuticals position peaked at $1.11M in Q1 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on AGF Management's 13F filing for Q1 2026, filed 7 May 2026.